上海兰卫医学检验所股份有限公司 关于公司董事、副总经理短线交易、违规减持公司股票 暨致歉的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：301060 证券简称：兰卫医学 公告编号：2024-024 上海兰卫医学检验所股份有限公司（以下简称"公司"）于近期获悉，公司董事、 副总经理毛志森先生原未持有公司股份，于 2024 年 3 月 21 日至 3 月 26 日期间买卖公 司股票，且其未提前将减持计划告知公司进行预披露。根据《中华人民共和国证券法》 《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上市公司股东、董监高 减持股份的若干规定》《深圳证券交易所上市公司股东及董事、监事、高级管理人员减 持股份实施细则》等法律法规的规定，毛志森先生以上行为涉嫌短线交易且构成违规减 持。 公司获悉后高度重视并进行了核查，由毛志森先生出具了《关于本人买卖兰卫医学 股票的情况说明及致歉函》。公司现将具体情况说明如下： 按照先进先出原则进行计算，本次短线交易的收益为-23, ...

一、行政监管措施决定书的内容 证券代码：301060 证券简称：兰卫医学 公告编号：2024-023 上海兰卫医学检验所股份有限公司 关于公司董事、副总经理收到中国证券监督管理委员会 上海监管局行政监管措施决定书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）董事、副总经理毛志森先 生于近日收到中国证券监督管理委员会上海监管局出具的《关于对毛志森采取出具警示 函措施的决定》（沪证监决〔2024〕223 号）。现将具体内容公告如下： 3．本次行政监管措施不会影响公司的正常经营管理。敬请广大投资者理性投资， 注意投资风险。 特此公告。 上海兰卫医学检验所股份有限公司 董事会 2024 年 5 月 21 日 毛志森： 经查，你作为上海兰卫医学检验所股份有限公司（简称"公司"）董事以及副总经 理，于 2024 年 3 月 21 日买入公司股票 16,300 股，成交金额 23.71 万元，于 2024 年 3 月 26 日卖出公司股票 9,000 股，成交金额 10.63 万元，且未按规定进行披露。 上述行为不 ...

证券代码：301060 证券简称：兰卫医学 编号：2024-001 上海兰卫医学检验所股份有限公司 投资者关系活动记录表 □特定对象调研 □分析师会议 □媒体采访  业绩说明会 投资者关系活动类 □新闻发布会 □路演活动 别 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称及人 通过全景网投资者关系互动平台（https://ir.p5w.net）参与公司本 员姓名 次2023年度网上业绩说明会的全体投资者 时间 2024年5 月15日（周三）下午15:00-16:30 公司通过全景网投资者关系互动平台（https://ir.p5w.net）采用网 地点 络远程的方式召开业绩说明会 董事长、总经理：曾伟雄先生； 董事、副总经理：毛志森先生； 上市公司接待人员 董事会秘书：高文俊先生； 姓名 财务总监：王锡谷先生； 独立董事：石道金先生； ...

证券代码：301060 证券简称：兰卫医学 公告编号：2024-022 上海兰卫医学检验所股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）第三届董事会第十八次会 议、第三届监事会第十六次会议审议通过了《关于回购公司股份方案的议案》。公司拟 使用自有资金通过深圳证券交易所股票交易系统以集中竞价交易方式回购公司部分人 民币普通股 A 股股份（以下简称"本次回购"），用于后期实施员工持股计划或股权激励 计划。本次回购的资金总额不低于人民币 1,500 万元（含），不超过人民币 3,000 万元 （含），回购股份的价格为不超过 21.09 元/股，不高于公司董事会通过回购决议前 30 个 交易日公司股票交易均价的 150%，回购股份的实施期限为自公司董事会审议通过回购 股份方案之日起 12 个月内。具体内容详见公司于 2023 年 11 月 16 日在巨潮资讯网披露 的《关于回购公司股份方案的公告》（公告编号：2023-056）及公司于 2023 年 11 月 20 日在巨潮资 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2024-018 上海兰卫医学检验所股份有限公司 关于提请股东大会授权董事会办理以简易程序 向特定对象发行股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开 了第三届董事会第二十次会议，审议通过了《关于提请股东大会授权董事会办理以简易 程序向特定对象发行股票的议案》，董事会同意提请股东大会授权董事会办理 2024 年度 以简易程序向特定对象发行股票融资总额不超过 3 亿元人民币且不超过最近一年末净 资产的 20%的股票，授权期限为公司 2023 年度股东大会通过之日起至 2024 年度股东 大会召开之日止（以下简称"本次发行股票"）。本次授权事宜尚需提请公司 2023 年度 股东大会审议。现将有关情况公告如下： 一、本次发行股票的具体内容 （一）本次发行证券的种类和数量 本次向特定对象发行股票募集资金总额不超过人民币 3 亿元且不超过最近一年末 净资产的 20%。本次发行股票的种类为中国境内上市的人民币普通股（ ...

募集资金年度存放与使用情况鉴证报告 上海兰卫医学检验所股份有限公司 容诚专字[2024]200Z0094 号 容诚会计师事务所(特殊普通合伙) 中国·北京 我们审核了后附的上海兰卫医学检验所股份有限公司（以下简称兰卫医学公 司）董事会编制的 2023 年度《关于募集资金年度存放与使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 本鉴证报告仅供兰卫医学公司年度报告披露之目的使用，不得用作任何其他 目的。我们同意将本鉴证报告作为兰卫医学公司年度报告必备的文件，随其他文件 一起报送并对外披露。 目 录 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 募集资金年度存放与使用情况鉴证报告 | | 1-3 | | 2 | 募集资金年度存放与使用情况专项报告 | | 4-6 | 募集资金年度存放与使用情况鉴证报告 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 外经贸大厦 15 层 / 922-926 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.c ...

兰卫医学：2023 年度会计师事务所的履职情况评估报告暨审计委员会履行监督职责情况报告 上海兰卫医学检验所股份有限公司 2023 年度会计师事务所的履职情况评估报告 暨审计委员会履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求，董事会 审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会 对容诚会计师事务所（特殊普通合伙）（以下简称"容诚会计师事务所"）2023 年 度履职情况的评估及履行监督职责的情况汇报如下： 一、会计师事务所基本情况 （一）基本情况 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通 合伙企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证 券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢外经贸大厦 901- 22 至 901-26，首席合伙人肖厚发。截至 2023 年 12 月 31 日，容诚会计师事务所 共有合伙人 17 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 436,441,198.76, representing a 5.78% increase compared to CNY 412,587,989.38 in the same period last year[5] - Net profit attributable to shareholders decreased by 95.00% to CNY 1,071,720.66 from CNY 21,413,081.32 year-on-year[5] - Basic and diluted earnings per share dropped by 94.95% to CNY 0.0027 from CNY 0.0535 year-on-year[5] - Net profit for Q1 2024 was CNY -264,826.54, a significant decrease from CNY 15,591,014.71 in Q1 2023[22] - Total operating revenue for Q1 2024 was CNY 436,441,198.76, an increase of 5.8% compared to CNY 412,587,989.38 in Q1 2023[21] - Total operating costs rose to CNY 410,500,506.73, up 11.2% from CNY 368,985,556.77 in the previous year[21] Cash Flow - The net cash flow from operating activities was negative at CNY -38,737,542.37, a decline of 162.75% compared to CNY 61,732,450.68 in the previous year[5] - Cash received from sales of goods and services was 420,445,869.80, down from 651,926,466.31 in the prior period, reflecting a decrease of approximately 35.4%[24] - Cash paid to employees decreased to 69,042,247.42 from 167,028,894.44, a reduction of about 58.7%[24] - Cash inflow from investment activities totaled 50,195,671.23, compared to 8,007,257.47 in the prior period, indicating a substantial increase[25] - Cash outflow for investment activities was 67,653,847.10, compared to 24,740,279.64 in the previous period, showing an increase of approximately 172%[25] - The net cash flow from financing activities was negative at CNY -14,143,681.47, a decline from CNY 11,309,552.97 in the previous period[25] - Cash inflow from financing activities decreased to 5,495,100.00 from 20,900,000.00, a decline of about 73.7%[25] - The company received 3,000,000.00 from minority shareholders, an increase from 1,000,000.00 in the previous period[25] - The impact of exchange rate changes on cash and cash equivalents was -165,527.41, contrasting with a positive impact of 32,217.55 in the prior period[25] Assets and Liabilities - Total assets decreased by 3.08% to CNY 2,894,810,431.30 from CNY 2,986,860,553.79 at the end of the previous year[5] - The company's total liabilities decreased to CNY 917,043,600.56 from CNY 1,006,695,890.02 year-over-year[20] - The total equity attributable to shareholders of the parent company was CNY 1,776,254,991.66, slightly down from CNY 1,780,316,277.50 in the previous year[20] - Total current assets decreased from 2,326,522,955.04 to 2,240,279,877.17, a reduction of approximately 3.7%[18] - Cash and cash equivalents decreased from 861,200,747.83 to 789,752,449.46, a decline of about 8.3%[17] - Accounts receivable increased from 1,010,473,055.69 to 1,032,983,314.49, an increase of approximately 2.3%[17] - Inventory decreased from 367,710,046.84 to 334,039,996.24, a reduction of about 9.2%[18] - Non-current assets decreased from 660,337,598.75 to 654,530,554.13, a reduction of about 0.9%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 32,038[13] - Shanghai Lanwei Investment Co., Ltd. holds 37.34% of shares, totaling 149,554,017 shares[13] - The total number of restricted shares at the end of the period is 220,277,568, with no shares released during the current period[15] - The company repurchased shares, resulting in a 50.05% increase in treasury stock to CNY 15,388,150.58 from CNY 10,255,144.08[10] Research and Development - Research and development expenses were CNY 9,985,811.02, a decrease from CNY 10,753,900.80 in the same period last year[21] - The company has no new product or technology developments reported in the current quarter[14] Other Financial Metrics - The weighted average return on equity fell to 0.06% from 1.03% year-on-year, a decrease of 0.97%[5] - The company reported a significant decline in other income, which fell by 88.14% to CNY 1,936,000.12 from CNY 16,326,865.98 in the same period last year[11] - The cash flow from financing activities was negative at CNY -14,143,681.47, a decrease of 225.06% compared to CNY 11,309,552.97 in the previous year[11] - The company reported a credit impairment loss of CNY -23,167,116.60, an improvement from CNY -35,517,924.09 in Q1 2023[21] - Cash flow details for Q1 2024 are yet to be disclosed in the report[23] - The company continues to focus on expanding its market presence and enhancing its service offerings[23]

Financial Performance - The company's main business revenue decreased significantly due to the decline in nationwide screening demand, resulting in a year-on-year decline in revenue [4]. - The profit distribution plan approved by the board proposes a cash dividend of 0 RMB per 10 shares, with no bonus shares or capital reserve conversion [5]. - The company reported a credit impairment loss during the reporting period, leading to a net loss for the year [4]. - The company’s operating revenue for 2023 was ¥1,674,368,547.18, a decrease of 60.13% compared to ¥4,199,305,065.95 in 2022 [17]. - The net profit attributable to shareholders for 2023 was a loss of ¥141,591,451.29, representing a decline of 122.94% from a profit of ¥617,322,755.95 in 2022 [17]. - The net cash flow from operating activities increased significantly to ¥546,988,461.38, up 549.88% from ¥84,167,038.10 in 2022 [17]. - The total assets at the end of 2023 were ¥2,986,860,553.79, down 20.28% from ¥3,746,874,320.81 at the end of 2022 [17]. - The company reported a basic earnings per share of -¥0.3535 for 2023, compared to ¥1.5413 in 2022, marking a decrease of 122.94% [17]. - The weighted average return on equity for 2023 was -7.35%, a drop of 41.74% from 34.39% in 2022 [17]. - The company experienced a net loss in each quarter of 2023, with the largest loss occurring in Q4 at -¥140,711,375.87 [20]. Market and Industry Trends - The company operates in the medical service industry, which is expected to see continued demand growth due to an aging population and increased health awareness [29]. - The clinical testing market in China grew from RMB 352.8 billion in 2017 to RMB 542.4 billion in 2021, with a compound annual growth rate (CAGR) of 11.4% and is expected to reach RMB 896.4 billion by 2026, with a CAGR of 10.6% [32]. - The national public budget for health and wellness in 2023 is set at RMB 242.11 billion, an increase of nearly RMB 16.7 billion compared to 2022, with health spending accounting for 8.8% of the total budget [33]. - The average financial subsidy for urban and rural residents' basic medical insurance has increased by RMB 30 to RMB 640 per person per year [33]. - The Chinese government is focusing on enhancing the capacity of county-level medical institutions and promoting the construction of national medical centers, which will drive demand for ICL services in these areas [34]. - The ICL industry is experiencing intensified competition, with a shift from a few service providers to numerous chain brands emerging nationwide [32]. - New technologies such as AI pathology diagnosis and automated laboratory systems are expected to drive innovation and transformation in the ICL industry [32]. - The Chinese clinical testing market remains in its early stages compared to developed countries, indicating significant potential for further market exploration [32]. Company Strategy and Operations - The company is focused on enhancing its medical testing and pathology diagnosis services despite the revenue decline [4]. - The company aims to enhance its influence in the medical and diagnostic fields through strategic collaborations with leading hospitals and research institutions [50]. - The company has established a scientific innovation center and partnered with Roche Diagnostics to create an "Innovation Demonstration Center" to enhance research capabilities [49]. - The company is focusing on building a multi-omics platform and has introduced cutting-edge technologies such as proteomics and metabolomics to support clinical research [49][50]. - The company has developed a "regional testing center + pathology center" model, enhancing its service capabilities in diagnostics and public health [64]. - The company has established a comprehensive professional medical service system, creating a replicable integrated regional center model [62]. - The company aims to provide personalized solutions through a flexible business model that integrates product agency and third-party services, catering to diverse customer needs [57]. - The company is committed to expanding its service ecosystem to enhance the capabilities of regional medical institutions in diagnostics and public health [64]. Financial Management and Governance - The company has a dedicated internal audit department that regularly checks the authenticity and completeness of financial information and internal control systems [136]. - The company strictly adheres to information disclosure regulations, ensuring timely and fair access to information for all investors [137]. - The company actively manages investor relations through various channels, including a dedicated investor relations phone line and email [138]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, and operations [140]. - The company has established an independent financial accounting system and can make independent financial decisions [143]. - The company held its annual general meeting on May 26, 2023, with a participation ratio of 62.72% [146]. - The company approved the 2022 annual report and financial budget for 2023 during the annual general meeting [146]. - The company has a clear ownership of major assets related to its operations, including land, property, and equipment [141]. Risks and Challenges - The company recognizes risks from policy changes in the healthcare system, which may impact its innovative business model and market rules [119]. - The company faces technological risks due to rapid advancements in the medical testing and pathology diagnosis industry, which may affect its competitive edge [120]. - The implementation of "volume-based procurement" policies may lead to significant price reductions, impacting the company's sales and profitability [122]. - The company is at risk of customer attrition and the inability to acquire new clients, which is crucial for maintaining revenue growth [124]. - The company is enhancing accounts receivable management to mitigate risks associated with long payment terms from healthcare institutions [125]. Human Resources and Talent Management - The company emphasizes the importance of high-quality technical and management talent for its development, especially with the expansion of its chain business and rapid technological updates [127]. - The company has established training and talent exchange mechanisms to attract high-level experts and continuously cultivate high-quality talent [127]. - The total number of employees at the end of the reporting period is 1,487, with 272 in the parent company and 487 in major subsidiaries [175]. - The company has 776 technical personnel, 211 sales personnel, and 440 administrative personnel, indicating a strong focus on technical expertise [175]. - The educational background of employees includes 10 with doctoral degrees, 52 with master's degrees, and 560 with bachelor's degrees, reflecting a highly educated workforce [175]. Shareholder and Board Activities - The company held two shareholder meetings during the reporting period, ensuring compliance with legal requirements and allowing shareholders to exercise their rights effectively [132]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements [134]. - The company has experienced the resignation of independent directors Liu Baohai, Sun Hongmei, and Wang Lei due to the expiration of their terms [150]. - The company has a diverse board with members holding various positions in other organizations, enhancing its governance and strategic direction [156][158]. - The company plans to repurchase shares, with specific proposals regarding the purpose and conditions of the buyback [167]. Environmental and Social Responsibility - The company promotes a low-carbon and environmentally friendly philosophy, integrating it into all aspects of its operations [199]. - There were no significant environmental penalties or issues reported during the reporting period [199].

上海兰卫医学检验所股份有限公司 2023 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合上海兰卫医学检验所股份有限公 司（以下简称"公司"）相关规章制度，在内部控制日常监督和专项监督的基础 上，我们对公司截至 2023 年 12 月 31 日（内部控制评价报告基准日）的内部控 制有效性进行了评价。 一、重要声明 兰卫医学：2023 年度内部控制自我评价报告 二、内部控制评价结论 本公司已按照既定内部控制检查监督的计划完成工作，内部控制检查监督的 工作计划涵盖了内部控制的主要方面和全部过程，为内部控制制度执行、反馈、 完善提供了合理的保证。 本公司按照逐步完善和满足公司持续发展需要的要求判断公司的内部控制 制度的设计是否完整和合理，内部控制的执行是否有效。判断分别按照内部环境、 风险评估、控制活动、信息与沟通、内部监督等要素进行。 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准 日，不存在财务报告内部控制重大缺陷，董事会认为，公司按照企业内部控制规 1 / 11 兰卫医学：2023 年度内部控制自我评 ...